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The subspecialty of cardio-oncology aims to reduce cardiovascular morbidity and mortality 
in patients with cancer or following cancer treatment. Cancer therapy can lead to a variety 
of cardiovascular complications, including left ventricular systolic dysfunction, pericardial 
disease, and valvular heart disease. Echocardiography is a key diagnostic imaging tool in the 
diagnosis and surveillance for many of these complications. The baseline assessment and 
subsequent surveillance of patients undergoing treatment with anthracyclines  
and/or human epidermal growth factor (EGF) receptor (HER) 2-positive targeted treatment 
(e.g. trastuzumab and pertuzumab) form a significant proportion of cardio-oncology 
patients undergoing echocardiography. This guideline from the British Society of 
Echocardiography and British Cardio-Oncology Society outlines a protocol for baseline 
and surveillance echocardiography of patients undergoing treatment with anthracyclines 
and/or trastuzumab. The methodology for acquisition of images and the advantages and 
disadvantages of techniques are discussed. Echocardiographic definitions for considering 
cancer therapeutics-related cardiac dysfunction are also presented.
Highlights
• Cardio-oncology patients account for an increasing 
proportion of echocardiography requests.
 • Accurate assessment of LV systolic function is critical 
to decision making in this patient group.
 • 2D LVEF, 3D LVEF, GLS, and RV assessment should 
be used in the echocardiographic assessment of these 
patients.
 • The clinical implications of a significant decline in GLS 
with potentially cardiotoxic cancer therapy require 
further investigation.
Advances in cancer detection and treatment have resulted 
in a growing number of cancer survivors. Cardio-oncology 
is a relatively new subspecialty that aims to prevent, 
detect, monitor and treat the cardiac complications of 
cancer therapy (1). The goal of the cardio-oncologist 
is to provide optimal cardiovascular care for patients 
with cancer in a multi-disciplinary setting involving 
oncologists, cardiologists, surgeons, cardiac physiologists/
scientists, specialist nurses, pharmacists, and allied 
health professionals (2). Cancer therapy-related cardiac 
dysfunction (CTRCD) is a frequently encountered clinical 
presentation, and transthoracic echocardiography is the 
cornerstone of its screening and detection.
The British Society of Echocardiography (BSE) has 
recently published an updated minimum dataset for a 
standard adult transthoracic echocardiogram (3). This 
cardio-oncology guideline is designed to be used in 
conjunction with the minimum dataset and provides 
guidance on transthoracic echocardiographic image 
acquisition and data interpretation in patients undergoing 
treatment with anthracyclines and/or trastuzumab.
This consensus guideline:
1. Defines the standard echocardiography protocol 
for the assessment of left ventricular (LV) function 
in those undergoing anthracyclines and/or human 
epidermal growth factor (EGF) receptor 2 (HER2)-
targeted therapy.
2. Defines cardiotoxicity and specifically CTRCD with 
anthracyclines and/or HER2-targeted therapy.
3. Provides strategies to enable the acquisition of high-
quality echocardiography for patients undergoing 
anthracyclines and/or HER2-targeted therapy.
4. Reviews the nonechocardiographic considerations 
for clinical decision making; reviews risk factors for 
cardiotoxicity; and provides guidance for referral to a 
cardio-oncology service.
Background
Anthracyclines (e.g. doxorubicin, epirubicin, 
daunorubicin, and idarubicin) and the monoclonal 
antibody trastuzumab (Herceptin, Genentech, South 
San Francisco, California) are commonly implicated 
in the development of LV dysfunction (4). Although 
there are other cardiotoxic anticancer therapies, in our 
experience, patients receiving anthracyclines and/or 
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echocardiograms performed, hence are the focus of 
this guideline. Trastuzumab may also be prescribed in 
combination with pertuzumab, another HER2-positive-
targeted monoclonal antibody, or with emtansine 
(Kadcyla/T-DM1, Genentech), which may be associated 
with additional cardiovascular concerns (5).
Many mechanisms are postulated to explain 
anthracycline-induced cardiotoxicity. Generation of 
excess reactive oxygen species and oxygen free radicals 
causing damage to DNA, RNA, proteins, and membrane 
lipids, and resultant cardiomyocyte death is one of the 
most commonly accepted cardiotoxicity mechanisms 
(6). The mechanisms responsible for trastuzumab-
related cardiotoxicity are less clear but likely are 
related to inhibition of the neuregulin-1 (NRG-1)/
ErbB signaling pathway (7). Commonly, but not in all 
cases, there is recovery of LV function with trastuzumab 
cardiotoxicity (8).
The addition of trastuzumab to anthracycline 
chemotherapy alone improves the overall survival of 
patients with HER2-positive tumors by approximately 
33%, with a 50% reduction in disease recurrence (9, 10). 
For this reason, the management of cardiac dysfunction 
should first consider the initiation of cardioprotective 
therapies, rather than withholding prognostically 
important oncology treatment. Management decisions 
require close collaboration between oncology 
and cardiology specialists. In addition, the risk of 
cardiotoxicity is not just an issue during oncology 
treatment (chemotherapy and/or radiotherapy) but can 
remain a concern for many years thereafter (11, 12).
The role of echocardiography and the 
recommended cardio-oncology protocol
All patients should undergo a comprehensive baseline 
echocardiogram to include the BSE minimum 
transthoracic dataset (3) with additional cardio-
oncology measurements (Table 1). Best practice for 
the minimum dataset for a targeted cardio-oncology 
protocol includes 2D and 3D volumes, LV ejection 
fraction (LVEF), global longitudinal strain (GLS), right 
ventricular (RV) size and systolic function assessment, 
tricuspid regurgitant velocity (TRV), and blood pressure 
measurement (Table 2). Measurement techniques are 
described in Tables 1 and 2, and the overall clinical 
approach to echocardiographic monitoring is described 
in Figure 1.
Baseline and serial 
echocardiographic assessment
The role of transthoracic echocardiography screening in 
the cardio-oncology setting is to assess cardiac function 
at baseline and to diagnose CTRCD at the earliest possible 
stage (Fig. 1). This enables informed decisions regarding 
timely commencement of cardioprotective medications 
and the safe continuation of cardiotoxic cancer therapy. 
It is crucial that accurate and reproducible parameters of 
LV systolic function are used so that a detected decline in 
LV systolic function truly reflects toxicity (13).
Baseline risk stratification of cardiotoxicity must 
take into consideration both the proposed cancer 
therapy and individual patient-related factors (Table 3). 
A more personalized tailored approach to surveillance 
is recommended in increased-risk patients compared 
with low-risk patients (Fig. 1). Recent Heart Failure 
Association–International Cardio-oncology Society 
expert position statements add to the published reports 
regarding the frequency of surveillance echocardiograms 
in patients stratified to low, medium, or high risk who 
then receive anthracyclines or trastuzumab (Table 4) 
(14, 15). In patients with normal LV systolic function at 
baseline, subsequent echocardiograms in asymptomatic 
patients should be targeted in the studies (Table 2). 
However, any patient with new cardiovascular symptoms 
while receiving cancer therapy should undergo a full 
echocardiogram (16).
The optimum frequency of echocardiograms during 
and after cancer therapy is unclear especially in the 
context of current pandemics (e.g. COVID-19) (17, 18). 
Recommendations for echocardiography during and after 
anthracycline-containing chemotherapy also differ, with 
the majority of guidelines not quantifying the frequency 
of monitoring (19, 20). There is a wide variation in the 
guideline recommendations (19) on the frequency of 
echocardiographic monitoring for patients receiving 
trastuzumab, ranging from every 3 months (21) to an 
undefined ‘periodically’ (10) (Table 4). Furthermore, 
there is no strong evidence to support a specific schedule 
of screening or any evidence that it improves outcomes 
for screened patients (22). However, screening every 3 
months is still recommended by the US Food and Drug 
Administration, although the frequency is admittedly 
controversial, and the compliance is limited (23).
Historically, trastuzumab has been temporarily 
held or even discontinued in patients who develop LV 
systolic dysfunction. However, there are increasing data 
to suggest that patients with asymptomatic reductions in 
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Table 1 Minimum requirements for baseline assessment for patients receiving anthracyclines/trastuzumab (in addition to the full 
BSE minimum dataset (3)).
View (Modality) Measurement Explanatory note Image
Vital signs Blood pressure, heart rate and rhythm
Apical 3D 3D volumes 
and LVEF
ECG signal with clear R-wave. Adjust 
scanner settings to ensure optimal 
resolution. Ensure ROI is within the 3D 
volume sector. Maximize the frame 
rate, adjusting number of subvolumes 
according to patient breath-holding 
capability as needed. Acquire images 
with the probe maintained in a steady 
position and at end-expiration. Before 
accepting acquisition, review volume 
and 9-slice view to ensure no stitch 
artifacts.
A4C/A3C/A2C GLS GLS 
measurement
Optimal ECG signal with minimal heart 
rate variability should be present across 
the three cardiac cycles. Heart rate 
variability will limit the calculation of 
GLS values, which can be problematic 
in patients with atrial fibrillation. 
High-quality image acquisition, 
maintaining a frame rate of 40 to 90 






































Clear endocardial and epicardial 
definition is required to ensure 
adequate segmental tracking 
throughout the cardiac cycle. Markers 
are placed in each of the respective 
basal and apical regions, using 
automated tracking where possible to 
maintain reproducible results. 
Automated tracking should also be 
combined with a visual assessment of 
tracking in each view across the whole 
ROI, including the endocardial and 
epicardial border. If more than two 
segments in any one view are not 
adequately tracked, the calculation of 
GLS should be avoided. 
 
 
3D, 3-dimensional; A2C, apical 2 chamber; A3C, apical 3 chamber; A4C, apical 4 chamber; BSE, British Society of Echocardiography; GLS, global longitudinal 
strain; LVEF, left ventricular ejection fraction; ROI, region of interest.
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Table 2 Cardio-oncology targeted echocardiogram reporting protocol.
View (modality) Measurement Explanatory note Image
Vital signs Blood pressure, heart rate 
and rhythm
A4C and A2C 2D Simpson’s biplane 
volumes and LVEF
Trace the endocardial 
border. Depending on the 
vendor, the MV level contour 
is made by a straight line at 
the beginning or end of 
tracing. LV length is defined 
as the distance between the 
mid-point of the MV-level 
line and the most distal 
point of the LV apex. Take 
care to ensure the LV is not 
foreshortened. Papillary 
muscles and trabeculations 
are included in the volumes 
and considered part of the 
chamber. Measure at 
end-diastole and end-
systole. Volumes indexed to 
BSA.
Apical 3D 3D volumes and 
LVEF
See Table 1
A4C/A3C/A2C GLS See Table 1
A4C LV TDI S′ Place sample volume (5 to  
10 mm) at or within 1 cm of 
the insertion of the MV 
leaflets. Angle of 
interrogation should be as 
parallel to Doppler beam as 
possible. Measure at 
end-expiration. Optimize 
scale and sweep speed  
(100 mm/s). Average both 
septum and lateral wall 





























RVD1: basal RV diameter. 
Measured at the maximal 
transverse diameter in the 
basal one-third of the RV. 
RVD2: mid-RV diameter 
measured at the level of the 
LV papillary muscles. RVD3: 
RV length, from the plane of 
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Peak TR velocity is measured 
by CWD across the tricuspid 
valve. Ensure the CWD to 
flow angle is correctly 
aligned. Eccentric jets can 
lead to incomplete Doppler 
envelopes and 
underestimation of TR 
velocity. A high sweep speed 
(100 mm/s) can help to 
differentiate between true 
velocities and artifact. 
Measure from a complete 
TR envelope. Choose the 
highest velocity. Accuracy is 
greatest when ultrasound 




A4C RV (TDI) RV S′ PW tissue Doppler S′ wave 
measurement taken at the 
lateral tricuspid annulus in 
systole. It is important to 
ensure the basal RV free 
wall segment and the lateral 
tricuspid annulus are 
aligned with the Doppler 
cursor to avoid velocity 
underestimation. A 
disadvantage of this 
measure is that it assumes 
that the function of a single 
segment represents the 
function of the entire 
ventricle, which is not likely 
in conditions that include 
regionality such as RV 
infarction. Normal value ≥ 9 
cm/s (27).
































This is an angle-dependent 
measurement, and 
therefore, it is important to 
align the M-Mode cursor 
along the direction of the 
lateral tricuspid or mitral 
annulus. Select a fast sweep 
speed. Measure total 
excursion of the tricuspid 







BSA, body surface area; CWD, continuous-wave Doppler; LA, left atrium; LV, left ventricle; MM, M-mode; MV, mitral valve; PW, pulsed wave; RV, right 
ventricle; RVD, right ventricular diameter; TAPSE, tricuspid annular plane systolic excursion; TDI, tissue Doppler imaging; TR, tricuspid regurgitation; TV, 
tricuspid valve; other abbreviations as in Table 1.
Table 2 Continued.
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LVEF to 40 to 49%, with guidance from a cardio-oncology 
team and personalized monitoring and treatment, 
can safely complete their cancer treatment without 
a significant increase in cardiac events (24, 25). We, 
therefore, recommend a personalized approach to patient 
surveillance, as emphasized in a position statement from 
the Heart Failure Association–European Association of 
Cardiovascular Imaging (15).
Echocardiography 3 to 12 months post-cardiotoxic 
treatment is recommended in all the patients, with the 
optimum timing dependent upon the individual 
patient’s risk (16). Appropriate frequency of repeat 
echocardiography thereafter remains to be fully defined 
and depends upon whether any cardiotoxicity occurred 
during the treatment phase (15), with international 
recommendations varying from 1- to 5-year intervals (16, 
26). Decisions regarding long-term surveillance should 
take into consideration a patient’s total anthracycline 
dose, exposure to other potentially cardiotoxic treatments 
(including radiotherapy), cardiovascular comorbidities, 
cardiotoxicity during treatment, and LV systolic function 
during and at the end of treatment.
Figure 1
Echocardiography protocol in patients undergoing 
treatment with anthracyclines/HER2-positive-
targeted therapy. Assessment at baseline, during 
therapy (including patients on indefinite 
HER2-positive-targeted therapy in case of 
metastatic disease) and long-term follow-up after 
the completion of cancer therapy. BSE, British 
Society of Echocardiography; GLS, global 
longitudinal strain; LV, left ventricular; LVEF, left 
ventricular ejection fraction.
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The definition of cardiotoxicity is varied and not limited 
to LV systolic dysfunction and CTRCD (19). The definition 
of cardiotoxicity based solely on LVEF also varies 
significantly (10, 16, 21). We define CTRCD as a decrease 
in LVEF by > 10% (10 absolute percentage points) to a 
value < 50%. This is in keeping with BSE-published normal/
borderline normal ranges (27) and European Society for 
Medical Oncology consensus recommendations (26). A 
LVEF of 50 to 54% is considered to be borderline low and 
will require more information before labeling the patient 
as having normal or abnormal LV systolic function.
We recommend that, if possible, 3D LVEF is measured 
due to both its reported superior reproducibility compared 
with 2D LVEF in patients undergoing anticancer therapy 
(28) and suggestions that 3D LVEF changes are more 
pronounced than and precede 2D LVEF changes in 
such patients (29). 3D LVEF has been shown to allow 
accurate serial quantification of LV systolic function and 
identification of changes in oncology patients (13). Decline 
in LVEF are usually accompanied by a significant change 
in GLS. Therefore, if GLS is normal in the presence of a 
reduced LVEF, a review of the echocardiograms to reassess 
the accuracy of all measurements is recommended. 
If there is still a significant and unexplained discrepancy 
between change in LVEF and GLS, adjudication with cardiac 
magnetic resonance (CMR) imaging should be considered.
Normal GLS values vary with age, sex, loading 
conditions, and different vendors; therefore, definition 
of abnormal GLS is not straightforward. It is important 
that heart rate and blood pressure are recorded because 
variation will need to be considered if there are temporal 
changes in GLS measurements. Much of the existing 
published reports on GLS values are based on General 
Electric vendor-specific data, and for the purpose of 
this guideline, we define a normal GLS value as being 
−17% or more negative for males and −18% or more 
negative for females (30, 31, 32). A relative change in 
sequential GLS > 15% (e.g. −22% to −18%) is considered 
to be significant (33). A worsening in GLS is known to 
predict a subsequent decline in LVEF, with GLS-guided 
cardioprotective therapy potentially reducing a decline in 
LVEF (34). The change in GLS is essential in recognition 
of cardiotoxicity, such that each patient acts as their 
own control. For this reason, comprehensive baseline 
echocardiography before cancer therapy is critical.
Reduction in GLS into the abnormal range as 
described or borderline values and decline in LVEF within 
the normal range should not be taken in isolation, 
especially in asymptomatic patients, but be interpreted in 
the overall clinical context. A decline in LVEF by > 10% 
points to an absolute value > 50% with a lower limit of 
Table 3 Identification of the patient at increased risk of cardiotoxicity.
Lower risk Increased risk
Therapy-related risk factors
Lower lifetime dose of anthracycline
< Doxorubicin 250 mg/m2 or equivalent
No previous anthracycline/trastuzumab-related cardiotoxicity
Absence of sequential anthracycline and trastuzumab therapy
Low-dose radiation therapy to central chest including heart in 
radiation field < 30 Gy
Increased lifetime dose of anthracycline
> Doxorubicin 250 mg/m2 or equivalent – high risk
> 400 mg/m2 or equivalent – very high risk
Prior anthracycline/trastuzumab-related cardiotoxicity
Sequential anthracycline and trastuzumab therapy
High-dose radiation therapy to central chest including heart in 
radiation field ≥ 30 Gy
Patient-related risk factors
Male
Age < 50 years
Absence of traditional cardiovascular risk factors: hypertension, 
smoking, obesity, dyslipidemia, insulin resistance
Past medical history: 
 Normal baseline LVEF
Absence of pre-existing cardiovascular disease (e.g. CAD, PAD, 
cardiomyopathy, severe valvular heart disease, heart failure, 
or diabetes)
 Normal kidney function or chronic kidney disease stage 1
Biomarkers: 
 Normal baseline troponin and/or NT-proBNP
 Normal cardiac troponin or NT-proBNP during cancer therapy
Female
Age 50 to 64 years – high risk and ≥ 65 years – highest risk
Presence of traditional cardiovascular risk factors: hypertension, 
smoking, obesity, dyslipidemia, insulin resistance
Past medical history: 
 Reduced or low-normal LVEF (50 to 54%) pre-treatment
Presence of pre-existing cardiovascular disease (e.g. CAD, 
PAD, cardiomyopathy, severe valvular heart disease, heart 
failure, or diabetes) 
Chronic kidney disease stage 2 + (eGFR < 78 mL/min/1.73 m2) (84)
Biomarkers: 
 Elevated* baseline troponin and/or NT-proBNP
Elevated* cardiac troponin or NT-proBNP during cancer therapy
*Elevated above the upper limit of normal for local laboratory reference range.
CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type 
natriuretic peptide; PAD, peripheral arterial disease.
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normal of GLS is a gray area that might suggest potential 
subclinical cardiotoxicity, although in some cases, it may 
reflect normal, physiological variability (35). In these 
circumstances, it is important to take other factors (such 
as symptoms, other echocardiographic parameters of LV 
systolic function, and biomarkers) into consideration. GLS 
may have added value, particularly in cases of borderline 
LVEF, with a normal strain measurement providing some 
reassurance (36, 37). Patients with normal LVEF, but 
abnormally low strain, also require further investigation 
to rule out potential causes such as cardiac amyloidosis, 
infiltration or hypertensive cardiomyopathy (38). 
These echocardiograms should be reviewed (to also ensure 
adequate technical quality) in conjunction with a clinical 
assessment and biomarker measurement. Certainly, 
there is a need for longer-term data to define the natural 
history of LVEF and GLS changes as well as the prognostic 
implications of potential subclinical cardiotoxicity.
Recommendations
Definition of cardiotoxicity by echocardiography:
 • LVEF: a decline in LVEF by > 10% (absolute percentage 
points) to a value < 50%,
Definition of probable subclinical cardiotoxicity by 
echocardiography:
 • LVEF: a decline in LVEF by > 10% (absolute percentage 
points) to a value ≥ 50% with an accompanying fall in 
GLS > 15% (where GLS measurement is available).
Table 4 Frequency of echocardiographic monitoring during anthracycline or trastuzumab (Anti-HER2) therapy according to the 
published guidelines.
Guideline, year (Ref. #) Recommendation for frequency of echocardiography during therapy
HFA-EACVI, 2020 (15)
 Anthracyclines Low risk*: after cycle of cumulative dose 240 mg/m2 doxorubicin or equivalent, then every 
additional 100 mg/m2 or every two cycles
Medium risk*: following 50% of planned total treatment and after cycle of cumulative dose  
240 mg/m2 doxorubicin or equivalent
High risk*: every two cycles, consider after every cycle above 240 mg/m2 doxorubicin or 
equivalent
 Anti-HER2 (neoadjuvant and 
adjuvant)
Low risk*: every four cycles (12 weeks)
Medium risk*: every three cycles (9 weeks), then reduce to every four cycles if stable at 4 months
High risk*: every two cycles (6 weeks), then reduce to every three cycles if stable at 4 months
 Anti-HER2 (long term) Low risk*: every four cycles in year 1, every six cycles in year 2, then reduce to every 6 months
Medium risk*: every three cycles, then if stable reduce to every 6 months
High risk*: every two or three cycles for 3 months, then reduce to every four cycles in year 1, 
then reduce frequency
ESMO, 2020 (26)
 Anthracyclines After a cumulative dose of 250 mg/m2 doxorubicin or equivalent, then after each additional  
100 mg/m2
 Anti-HER2 Every 3 months (higher-risk patients may require more frequent monitoring)
 Anti-HER2 (long term) General surveillance, which may include cardiac imaging
ASCO, 2017 (16)
 Anthracyclines Frequency of surveillance should be determined by health care providers; routine surveillance 
imaging may be offered in patients considered to be at increased risk of cardiac dysfunction
 Anti-HER2 Frequency of surveillance should be determined by health care providers; routine surveillance 
imaging may be offered in patients considered to be at increased risk of cardiac dysfunction
CCS, 2016 (85)
 Anthracyclines No recommendation made
 Anti-HER2 Every 3 months
ESC, 2016 (10)
 Anthracyclines After 200 mg/m2 of doxorubicin or equivalent
 Anti-HER2 Every four cycles
ASE, 2014 (33)
 Anthracyclines After 240 mg/m2 of doxorubicin or equivalent, then after each additional 50 mg/m2
 Anti-HER2 Every 3 months
*Risk is calculated according to therapy and patient-related factors, including age, and cardiovascular risk factors. For more details, the reader is directed 
to the original guideline (15).
ASCO, American Society of Clinical Oncology; ASE, American Society of Echocardiography; CCS, Canadian Cardiovascular Society; EACVI, European 
Association of Cardiovascular Imaging; ESC, European Society of Cardiology; ESMO, European Society of Medical Oncology; HER, human epidermal growth 
factor; HFA, Heart Failure Association.
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Definition of possible subclinical cardiotoxicity by 
echocardiography:
 • LVEF: a decline in LVEF by < 10% (absolute percentage 
points) to a value < 50%.
or
 • LV GLS: a relative percentage reduction in GLS by 
> 15% from the baseline value.
The detection of cardiotoxicity or probable/possible 
subclinical cardiotoxicity is achieved via advanced 
echocardiographic measures (2D/3D LVEF and GLS). For 
best practice, centers undertaking surveillance of these 
patients should have the ability to perform 2D/3D LVEF 
and GLS assessment.
LV function assessment by echocardiography
Cardiac rhythm and rate
Sequential assessments for those not in sinus rhythm 
may be problematic. In atrial fibrillation due to the 
persistent variation in cardiac cycle length, measures 
of ventricular systolic and diastolic function may have 
limited reliability. When preceding and pre-preceding 
RR intervals are within 60 ms of each other and both 
exceed 500 ms, measures of systolic function on a 
single beat are similar to those averaged over 15 cycles 
of varying durations (39). These findings suggest that 
selection of beats with similar RR intervals is more 
important for reproducibility than the total number of 
measurements made.
Blood pressure
Recording of blood pressure is essential because parameters 
such as LVEF, tissue Doppler indices, and GLS are load 
dependent. A substantial increment of blood pressure 
may be responsible for an apparent change in function, 
without necessarily indicating myocardial disease, 
because poorly controlled hypertension is associated with 
abnormal strain (40).
Accurate assessment of 2D LVEF
LVEF is one of the most commonly used echocardiographic 
methods to assess LV systolic function. This represents 
the fraction of blood within the LV that is ejected in 
one cardiac cycle. Because it is difficult to quantify a 3D 
structure using 2D imaging, the techniques developed 
with 2D echocardiography rely on measuring the ventricle 
in standard planes.
We do not support the use of qualitative ‘eyeball’ 
assessments to determine LVEF values or ranges. The 2D 
volumetric Simpson’s method for the assessment of LVEF 
is based on the principle of slicing the LV from the apex 
down to the mitral valve (MV) into a series of discs. The 
volume of each disc is then calculated using the diameter 
and thickness of each slice. It is assumed that the LV 
is circular at each level. Accuracy is improved by using 
diameters in two planes, separated by 60° of rotation 
(apical 4 and 2 chamber) so that the disc surface area is 
more precisely defined. Acquisitions should be made at 
end-respiration, and the image should be adjusted using 
gain, compress, and dynamic range to ensure optimal 
endocardial delineation and elongation of the entire LV 
length, without foreshortening. High-quality images are 
critical for accurate quantification. For more detailed 
guidance, the reader is directed to the BSE minimum 
dataset (3). The endocardial surface should be traced at 
end-diastole and end-systole to encompass the whole of 
the LV. Papillary muscles and trabeculations are excluded 
from the endocardial tracing and are considered part of 
the chamber. This can be achieved either on the machine 
or by using an off-line analysis software package. LVEF 
is calculated as the difference between end-diastolic 
volume and end-systolic volume (stroke volume) as a 
percentage of the end-diastolic volume. Intraobserver 
and interobserver variability has been reported as 3.3 and 
4%, respectively with a minimum detectable difference 
of 9 to 11% (13, 41). When describing 2D LVEF, the 
report conclusion should always note the most recent 
estimate of LVEF and include a comparison with the 
baseline value.
3D LVEF
The 2D echocardiographic assessment of LVEF has 
inherent limitations because it makes geometric 
assumptions of the LV. This consideration is especially 
important for serial echocardiograms because exact plane 
duplication is almost impossible. 3D echocardiography, 
although still requiring high-quality, reproducible 
images, is an advance on the Simpson’s method because 
it allows contouring of the cavity within the 3D space 
of the echocardiographic volume acquisition. Therefore, 
there is no assumption that the short-axis view of the 
ventricle is circular. Instead, one can contour the actual 
shape of the ventricle in all dimensions. Consequently, 
3D LVEF calculation has a smaller detected percent 
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change of approximately 5 to 8% and, because it is 
semiautomated, has better intra- and interobserver 
variability (13). There is superior temporal variation of 
3D LVEF compared with 2D LVEF over a 12-month period 
in stable patients receiving chemotherapy (3% vs 5%) 
(13). Commercially available scanners contain software 
tools that allow the 3D assessment of LV volumes and 
LVEF. It is to be remembered, however, that 3D imaging 
remains sensitive to image quality, and it is good practice 
to record and analyze both 2D and 3D images, because 
deterioration of image quality during follow-up is most 
likely to affect 3D images. There remains some variation 
in 3D LVEF calculation between specific vendors, and we 
recommend that the same machine and analysis software 
are used for serial echocardiograms (42). When reporting 
3D LVEF findings, the conclusion should always note 
the most recent estimate of LVEF and should include a 
comparison to the baseline value.
Full-volume datasets allow the generation of a 3D 
dataset with the final image of the heart created by 
acquiring several single or several subvolumes over the 
corresponding number of sequential cardiac cycles. 
Attention to breath-hold is essential to avoid stitching 
artifact. The greater the number of subvolumes used, the 
higher the frame rate and temporal resolution, albeit 
at greater risk of stitching artifact. Newer technology 
allows increased volume rates and reduced time for 
complete cardiac volume acquisition in the estimation 
of 3D LVEF, making it comparable to CMR imaging 
(43). It should be recognized that there is a trade-off 
between temporal and spatial resolution. Temporal 
resolution (i.e. volume or frame rate) allows localization 
of an anatomic structure in a point in time. This can 
be improved by reducing the sector size (width and 
depth). Spatial resolution is the ability to differentiate 
two points in space and is dependent on the number 
of scan lines per volume (scan line density), However, 
increasing scan lines lengthens the acquisition time and 
lowers the volume rate (44).
Images should be obtained during shallow breathing, 
preferably in end-expiration. If deep inspiration is 
needed to obtain optimal image quality, this should 
be documented in the echocardiogram report so that it 
can be reproduced at the next visit. Finally, it is good 
practice for the sonographer to quantify LVEF on 2D and 
3D images while the patient is still present. Performing 
the analysis at the same time also allows repeat image 
acquisition in case of contouring difficulty.
How to acquire 3D echo volumes for LVEF assessment:
 • Ensure high-quality ECG trace with a clear R-wave. 
This enables appropriate 3D full-volume triggering.
 • Ensure the region of interest (ROI) is within the 3D 
volume sector. Reduce the sector as needed to focus 
on the ROI.
 • As for 2D imaging, adjust scanner settings so that the 
best 3D resolution is available.
 • Adjust gain appropriately. Low gain settings result in 
echo ‘dropout’, and excess gain reduces resolution 
and causes a loss of the 3D perspective or depth in the 
dataset.
 • Optimize frame rate and adjust number of subvolumes 
according to the patient’s breath-holding capacity as 
needed.
 • Acquire images with the probe maintained in a steady 
position and at end-expiration.




Inadequate LV endocardial border definition can lead 
to errors in LV volume and LVEF estimation. Accurate 
LVEF assessment is particularly important where values 
obtained fall on boundaries that influence treatment 
decisions. Poor endocardial definition can occur in patients 
undergoing cancer treatment (e.g. following mastectomy, 
chest irradiation, or breast reconstruction surgery) (33) or 
secondary to body habitus. The use of echocardiographic 
contrast for LV chamber opacification is now widely 
accepted when two contiguous LV segments from any apical 
view are not adequately visualized on noncontrast images 
(45). Tracing LV borders more reliably leads to inclusion 
of LV trabeculation within the LV cavity after contrast. 
As a result, LV volumes (both in systole and diastole) are 
commonly greater than those recorded with noncontrast 
imaging, although LVEF is usually analogous. The minimum 
detectable difference for 2D contrast LVEF has been noted to 
be in the order of 4% (46), which is significantly better than 
the 9 to 11% for noncontrast 2D LVEF. However, the superior 
performance of LV contrast has not been consistently 
proven. One study demonstrated inferior reproducibility 
with contrast echocardiograms compared with noncontrast 
2D and 3D echocardiograms (13). Use of the same 
methodology in sequential testing is thus recommended. 
It is to be noted that the use of contrast has unpredictable 
effects on 2D speckle tracking and is best done after 
strain acquisition.
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Tissue Doppler assessment of systolic and 
diastolic function
Tissue Doppler echocardiography has become an 
established component of the diagnostic ultrasound 
examination, enhancing interrogation of myocardial 
motion. Although LVEF reflects the sum contribution 
of several regions, it does not provide information on 
regional function or on the underlying myocardial 
mechanical activity. Conventional Doppler techniques 
assess velocity of blood flow by measuring high-
frequency, low-amplitude signals from small, fast-moving 
blood cells. Tissue Doppler imaging (TDI) uses the same 
Doppler principles to quantify the higher-amplitude, 
lower-velocity signals of myocardial tissue motion. TDI 
depicts myocardial motion at a specific location in the 
heart. High-velocity signals from the blood are filtered 
out and amplification scales suitably adjusted so that 
Doppler signals from tissue motion can be recorded. 
Tissue velocity indicates the rate at which a particular 
point in the myocardium moves toward or away from the 
transducer. The accuracy of TDI is angle dependent and 
only measures the vector of motion that is parallel to the 
direction of the ultrasound beam. Mean mitral annular S′ 
should be acquired at end expiration. For more detailed 
guidance, the reader is directed to the BSE minimum 
dataset (3). Normal age-related values for mean mitral 
annular S′ are described in recent guidance (27). Both 
tissue Doppler and gray scale imaging have been used to 
calculate mitral annular plane displacement, which is a 
longitudinal function parameter analogous to strain.
In breast cancer patients receiving anthracyclines 
with or without trastuzumab, diastolic dysfunction has 
been reported to precede systolic dysfunction and CTRCD 
(47). We recommend that diastolic assessment should be 
undertaken in all baseline echocardiograms. Along with 
mitral E and A maximum velocity (Vmax), E/A ratio, left 
atrial volumes, and TRV, TDI is a key part of the assessment 
of diastolic function (48). For more details on the grading 
of diastolic function, the reader is directed to the current 
American Society of Echocardiography/European 
Association of Cardiovascular Imaging guidelines on the 
assessment of diastolic dysfunction (49).
Speckle tracking echocardiography GLS
The term strain refers to an object’s fractional or percentage 
change from its original, unstressed dimension and 
reflects the deformation of a structure. When applied to 
myocardium, this deformation or strain directly describes 
the contraction/relaxation pattern. At rest, an object that 
has an initial length (L0) can be stretched or compressed to a 
new length (L). This change in length is usually represented 
as a percentage, with a negative score indicating a shortening 
in length. If L equals L0, then strain remains zero.
Although LVEF is simple and intuitive, and supported 
by prognostic information, it has important limitations 
including image quality dependence, geometric 
assumptions, and insensitivity to early disease (which is 
characterized by disturbances of longitudinal function). 
Strain measurements, like LVEF measurements, are 
dependent on endocardial border tracing and therefore 
also rely on image quality.
The myocardial fiber orientation of the LV is 
complex. The major limitation of the Doppler-based 
approach is the angle dependency required during 
image acquisition (50, 51). This has been overcome by 
speckle tracking echocardiography, which is based on 
tracking the pattern of speckles generated by reflected 
ultrasound signal. Different regions of myocardium have 
a unique speckle pattern that moves from one frame to 
the next. Dedicated speckle tracking software enables 
this movement to be quantified via several parameters 
(such as longitudinal strain).
GLS is measured using a combination of the apical 
2-chamber (A2C), 3-chamber (A3C), and 4-chamber (A4C) 
views (52). Longitudinal strain is the degree of deformation 
from base to apex. During systole, contraction in this 
plane leads to fiber shortening, represented as a negative 
percentage value (i.e. the more negative the value, the 
greater the deformation). Although global circumferential 
and radial strain may also indicate cardiotoxicity, there 
are less data to support their clinical use (35); hence, 
the focus on GLS. GLS has been shown to be superior 
to 2D LVEF with regard to reproducibility in patients 
receiving trastuzumab (53) and has been suggested that it 
is more reproducible with appropriate echocardiographic 
training (54). It is therefore best practice that cardio-
oncology echocardiograms are performed on machines 
that are able to calculate GLS and which have 3D 
capabilities. Small, but statistically significant, differences 
between vendors exist; therefore, the same acquisition 
platform and analysis software should be used for serial 
echocardiograms (55, 56, 57). The ability to perform 
GLS and 3D measurements is beyond the current 
BSE personal accreditation standards. It is, therefore, 
important that individuals undertaking cardio-oncology 
echocardiograms are suitably trained in acquisition 
and analysis of these advanced echocardiography 
measures in a reproducible and consistent manner. 
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In addition, echo departments should establish and 
reassess their intra- and interobserver variability of 2D 
LVEF, 3D LVEF, and GLS.
How to perform GLS:
 • GLS is calculated using the standard A3C, A4C, and 
A2C views.
 • Ensure that an optimal ECG signal with minimal heart 
rate variability is present across the three cardiac cycles.
 • Maintain a frame rate of 40 to 90 frames/s (33) at a 
normal heart rate.
 • Focus on the LV with appropriate adjustment of width 
and depth.
 • The technique used to select the appropriate ROI is 
vendor specific, and the reader is advised to consult 
individual machine/software technical guidelines 
for further guidance. For General Electric machines/
software, adjust the overlay for the ROI. In the A4C 
view, the ROI begins at the septal MV annulus, 
progresses to the apex, and ends at the lateral MV 
annulus. In the A2C view, the ROI starts at the inferior 
MV annulus and extends through to the apex and then 
to the anterior wall MV annulus. In the A3C view, the 
ROI starts at the posterior wall MV annulus, extends 
to the apex and finally to the base of the septal wall, 
taking care not to extend into the LV outflow tract.
 • Two contours for speckle tracking are visible and 
should be aligned with the relevant area of interest:
 ○ The endocardial border – the inner contour of the 
myocardium.
○ The epicardial border – the outer border of the 
myocardium (be careful to exclude the pericardium, 
especially if automated analysis software is 
used. Inclusion of pericardium will lead to an 
underestimation of strain).
 • Use optimal gain settings and breath-holding 
techniques to clearly delineate the endocardial and 
epicardial borders.
 • During post-processing, the ROI should be aligned 
as accurately as possible to reflect the 17-segment 
LV model.
Right heart assessment
Right heart (RH) structure and function have not 
traditionally been incorporated into the definition of 
CTRCD. However, there is increasing evidence that RH 
abnormalities may be prognostically significant (58, 59), 
and, therefore, assessment of the RH should be obtained 
to include RV dimensions, RV S′, tricuspid annular 
plane systolic excursion, and TRV. Abnormalities in RH 
structure and function on serial echocardiography should 
be discussed with a cardio-oncologist and may require full 
assessment of the RH as per the BSE practical guideline for 
RH assessment and the BSE guideline on the assessment of 
pulmonary hypertension (60, 61).
Alternative imaging modalities
Although echocardiography remains the first-line 
investigation for the detection of CTRCD, there is a 
complementary role for other imaging modalities, 
particularly in patients with inadequate echocardiographic 
windows. Traditionally, multigated acquisition scans 
have been used in the assessment of LV systolic function, 
however, the associated radiation exposure (a particular 
issue with the inevitable serial scans) and limited structural 
information available makes this an inferior investigation 
(62). CMR imaging may be required in patients with poor 
echocardiographic windows or for tissue characterization 
(e.g. cardiac masses and cancer treatment-related 
myocarditis). Low inter- and intrareader variability make 
it the optimal technique for detecting small changes in 
LVEF in serial scans; however, its use is still limited by its 
availability and cost (63, 64). The role of cardiac CT is 
mainly in the noninvasive evaluation of coronary artery 
disease, but it can also be used to assess pericardial disease 
and valvular heart disease and in the imaging of cardiac 
tumors (65, 66).
Recommendation
• Contrast 2D echocardiography should be considered 
when subendocardial definition precludes the accurate 
assessment of LVEF, that is, when a minimum of two 
contiguous LV segments from any apical view are not 
seen on noncontrast images (45).
 • Depending on local expertise and availability, CMR 
imaging is an alternative modality, particularly for 
patients with poor echocardiographic windows.
 • The same imaging modality should be used for 
sequential scans.
Clinical risk stratification for cardiotoxicity
Risk stratification for cardiac dysfunction is recommended 
before the commencement of potentially cardiotoxic 
cancer treatment in all patients (14, 16). A clinical history 
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and cardiovascular examination, including blood pressure 
measurement, should be performed in order to aid 
assessment of risk (Table 3). All patients should also have 
a baseline 12-lead ECG.
Although it is outside the scope of this document, 
biomarkers (troponin and N-terminal pro-B-type natriuretic 
peptide (NT-proBNP)) may be considered in high-risk 
patients to assist further risk stratification (Table 3). 
Biomarkers may be able to detect subclinical signs of 
LV systolic and diastolic dysfunction before a decline in 
LVEF (67). Elevated baseline levels should prompt more 
frequent monitoring because there is some evidence that 
abnormal baseline high-sensitivity troponin is associated 
with an increased risk of developing complications with 
chemotherapy. There is also an association between 
troponin release after high-dose chemotherapy and 
subsequent cardiac events (68, 69, 70). Persistent serial 
elevation of NT-proBNP is associated with an increased 
risk of developing overt heart failure, whereas a transient 
rise is not (71). However, discussion of the utility and 
prognostic value of biomarkers is beyond the scope of 
this guideline, and the reader is directed to additional 
references (27, 72).
Defining the high-risk patient is challenging. 
Although there is no validated unifying risk calculator 
that is applicable to all cancer types and therapies (73), 
recently published guidelines can help clinicians with risk 
stratification (14). This highlights the need for a tailored 
and individualized approach to the assessment, treatment, 
and monitoring of cardio-oncology patients.
Referral to a cardio-oncology service
The cardio-oncology team is composed of specialized 
health care professionals who work together to provide 
‘consistent, continuous, coordinated and cost-effective 
care during the cancer process’ (74). This highly specialized 
service is involved in patient care, cardio-oncology 
research, and regional co-ordination of services (75).
Echocardiography is pivotal to decision making in 
cardio-oncology, for example, when to consider referral 
to a cardio-oncologist, when to initiate cardioprotective 
medications or heart failure therapy, and when to hold 
or discontinue cardiotoxic cancer therapy. Early detection 
of cardiac dysfunction, with prompt initiation of 
cardioprotective medications, increases the likelihood of 
LVEF recovery and may reduce the cardiac event rate (76).
All patients with confirmed cardiotoxicity require 
referral to a cardio-oncology service. Any patient with 
pre-existing LV systolic dysfunction should be discussed 
with the cardio-oncology team, ideally before the 
commencement of cardiotoxic cancer therapy (2). With 
increasing evidence that a significant reduction in GLS 
accurately predicts subsequent cardiotoxicity (35), referral 
to a cardio-oncology service for expert review could be 
considered in patients with > 15% reduction in GLS 
despite a normal LVEF.
Treatment thresholds
Patients who develop CTRCD (symptomatic or 
asymptomatic) benefit from early introduction of 
angiotensin-converting enzyme inhibitors/angiotensin 
receptor blockers and/or beta-blockers (77). Treatment 
thresholds vary in the published reports (10, 78, 79). 
Treatment in asymptomatic patients with declines in GLS, 
but not in LVEF, remains controversial (13, 80). Closer 
monitoring and/or starting cardioprotective treatments 
are options to be considered. There is no evidence at 
present to hold cancer therapy based upon abnormal 
strain measurements alone.
Table 5 Key echocardiographic recommendations for best practice.
Baseline assessment Full BSE minimum dataset echocardiogram, vital signs, and GLS/3D volumes (see Table 1)
Follow-up assessment Targeted echocardiogram (see Table 2).
If new symptoms, then full echocardiogram as per baseline assessment
Definition of cardiotoxicity LVEF: a decrease in LVEF by >10% (absolute percentage points) to a value < 50%
Definition of probable cardiotoxicity by 
echocardiography
LVEF: decrease in LVEF by >10% (absolute percentage points) to a value ≥ 50% with an 
accompanying fall in GLS > 15% (where GLS measurement available)
Definition of possible cardiotoxicity by 
echocardiography
LVEF: a decrease in LVEF by <10% (absolute percentage points) to a value < 50% or LV 
GLS: when LVEF ≥ 50%, a relative percentage reduction in GLS by > 15%
Poor endocardial definition Consider contrast echocardiography when endocardial definition precludes the accurate 
assessment of LVEF (e.g. when a minimum of two contiguous LV segments from any 
apical view are not seen on noncontrast images)
Depending on local expertise and availability, CMR imaging is an alternative modality in 
this context
CMR, cardiac magnetic resonance; other abbreviations as in Tables 1, 2 and 3.




https://erp.bioscientifica.com © 2021 The authors
Published by Bioscientifica Ltd
R Dobson, A K Ghosh et al. Echocardiography guideline 
for anthracyclines and/or 
trastuzumab
G158:1
Recent studies have investigated the role of pre-
treatment with cardioprotective medications in cancer 
patients embarking on cardiotoxic therapy (81, 82, 83). 
Results have been mixed, and such strategies cannot 
currently be recommended as routine practice.
Conclusions
Cardio-oncology is a relatively new and rapidly developing 
subspecialty. Echocardiography is a key imaging modality 
in the initial assessment and subsequent monitoring of 
patients treated with commonly used cardiotoxic drugs such 
as anthracyclines and trastuzumab. High-quality targeted 
LVEF assessment incorporating 3D volumetric analysis 
and strain measurement can be used to safely monitor 
patients during and after treatment. Key echocardiographic 
recommendations are shown in Table 5.
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